Clin Kidney J. 2016 Aug;9(4):630-5. doi: 10.1093/ckj/sfw049. Epub 2016 Jun 10.

Low-molecular weight heparin infusion as anticoagulation for haemodialysis.

Clinical kidney journal

Steve Siu-Man Wong, Wai-Yan Lau, Ping-Kwan Chan, Ching-Kit Wan, Yuk-Lun Cheng

PMID: 27478610 PMCID: PMC4957725 DOI: 10.1093/ckj/sfw049

Abstract

BACKGROUND: Low-molecular weight heparin (LMWH) is commonly used as an anticoagulant for haemodialysis by a single-bolus injection. However, its application in extended haemodialysis has been infrequently studied. In particular, for nocturnal home haemodialysis patients sleeping throughout treatment, the need for additional intradialytic bolus might render the use of LMWH impractical. To overcome this limitation, we changed traditional bolus injections to continuous infusion. We first tested our method among in-centre 4-h haemodialysis patients to establish a feasible and safe infusion regimen before utilizing it in extended dialyses at home.

METHODS: Recruited patients were given nadroparin (standardized at 65 IU/kg) as an anticoagulant for haemodialysis. They were first randomized to receive nadroparin either by bolus injection or infusion. Afterwards, the patients underwent crossover to receive the alternate method of LMWH anticoagulation. The degrees of anticoagulation and bleeding complications were compared.

RESULTS: Sixteen haemodialysis patients were recruited. After nadroparin administration, anti-Xa levels at the first hour were significantly higher by the bolus than the infusion methods (0.68 ± 0.10 versus 0.49 ± 0.10 IU/mL, P < 0.001) and were similar by the second hour (0.56 ± 0.10 versus 0.55 ± 0.11 IU/mL, P = 0.64). At the sixth hour, anti-Xa levels by the infusion method were significantly higher (0.35 ± 0.13 versus 0.25 ± 0.10 IU/mL, P < 0.001), suggesting the infusion approach required a dosage reduction. There were no bleeding events reported in either method.

CONCLUSIONS: LMWH infusion is feasible and safe. The method avoids early excessive anticoagulation caused by bolus injection and reduces the LMWH dose. Future studies should be conducted to evaluate LMWH infusion in extended haemodialysis treatment.

Keywords: anticoagulation; continuous infusion; haemodialysis; low-molecular weight heparin; nadroparin

References

1. Crit Care. 2009;13(6):R193 - PubMed
2. CANNT J. 2008 Oct-Dec;18(4):32-5 - PubMed
3. Nephrol Dial Transplant. 2003 Nov;18(11):2348-53 - PubMed
4. Adv Ren Replace Ther. 1995 Oct;2(4):295-304 - PubMed
5. Kidney Int. 1991 Sep;40(3):496-500 - PubMed
6. Int J Artif Organs. 2001 Jul;24(7):447-55 - PubMed
7. Am J Kidney Dis. 2002 Sep;40(3):531-8 - PubMed
8. Nephron. 2002;92(3):589-600 - PubMed
9. BBA Clin. 2015 Mar 30;3:276-9 - PubMed
10. Intensive Care Med. 2007 Sep;33(9):1571-9 - PubMed
11. NDT Plus. 2011 Dec;4(Suppl 3):iii19-iii20 - PubMed
12. Neth J Med. 2015 Jul;73(6):270-5 - PubMed
13. J Am Soc Nephrol. 2004 Dec;15(12):3192-206 - PubMed
14. Blood. 2005 Oct 15;106(8):2710-5 - PubMed
15. Nephrol Dial Transplant. 2002 Dec;17(12):2231-8 - PubMed
16. Am J Kidney Dis. 2006 Jul;48 Suppl 1:S2-90 - PubMed
17. Nephrology (Carlton). 2009 Aug;14 (5):455-61 - PubMed
18. Kidney Int. 1988 Apr;33(4):890-6 - PubMed
19. Thromb Res. 1992 Mar 1;65(4-5):641-50 - PubMed

Publication Types

• Journal Article